Literature DB >> 3283358

Evaluation of a functional index and an articular index in ankylosing spondylitis.

M Dougados1, A Gueguen, J P Nakache, M Nguyen, C Mery, B Amor.   

Abstract

We describe an index of functional impairment and a system of scoring joint tenderness for use in the assessment of ankylosing spondylitis. The functional index consists of 20 questions and the articular index is based on the scoring of a total of 10 joint responses after movement or firm digital pressure. These indices are simple to establish and not time consuming. They have a high degree of intra- and interobserver reproducibility. The indices showed changes in short term clinical trials of antiinflammatory drugs; these changes were highly correlated with the patient's overall assessment of his own clinical condition.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3283358

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  33 in total

1.  Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.

Authors:  E Kruithof; F Van den Bosch; D Baeten; A Herssens; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

2.  Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Authors:  F Van den Bosch; E Kruithof; D Baeten; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 3.  Impairment measures in rheumatic disorders for rehabilitation medicine and allied health care: a systematic review.

Authors:  Raymond A H M Swinkels; Lex M Bouter; Rob A B Oostendorp; Cornelia H M van den Ende
Journal:  Rheumatol Int       Date:  2005-06-24       Impact factor: 2.631

4.  Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo.

Authors:  B Vander Cruyssen; F De Keyser; E Kruithof; H Mielants; F Van den Bosch
Journal:  Ann Rheum Dis       Date:  2007-01       Impact factor: 19.103

5.  Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis.

Authors:  L C Doward; A Spoorenberg; S A Cook; D Whalley; P S Helliwell; L J Kay; S P McKenna; A Tennant; D van der Heijde; M A Chamberlain
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

6.  Polymorphism of the LMP2 gene and disease phenotype in ankylosing spondylitis: no association with disease severity.

Authors:  W P Maksymowych; N Adlam; D Lind; A S Russell
Journal:  Clin Rheumatol       Date:  1997-09       Impact factor: 2.980

7.  Evaluation of the Turkish version of the Dougados functional index in ankylosing spondylitis.

Authors:  Huseyin T E Ozer; Tunay Sarpel; Bozkurt Gulek; Z Nazan Alparslan; Eren Erken
Journal:  Rheumatol Int       Date:  2005-03-02       Impact factor: 2.631

8.  Factors related to change in global health after group physical therapy in ankylosing spondylitis.

Authors:  A Hidding; S van der Linden
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

9.  Ossification of the posterior longitudinal ligament in three geographically and genetically different populations of ankylosing spondylitis and other spondyloarthropathies.

Authors:  C Ramos-Remus; A S Russell; A Gomez-Vargas; A Hernandez-Chavez; W P Maksymowych; J I Gamez-Nava; L Gonzalez-Lopez; A García-Hernández; E Meoño-Morales; R Burgos-Vargas; M E Suarez-Almazor
Journal:  Ann Rheum Dis       Date:  1998-07       Impact factor: 19.103

10.  The Turkish versions of the Bath Ankylosing Spondylitis and Dougados Functional Indices: reliability and validity.

Authors:  Altinay Goksel Karatepe; Yesim Akkoc; Servet Akar; Yesim Kirazli; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2004-07-10       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.